Neurology News

The plasma biomarker P-tau217 predicted cognitive decline in patients with preclinical Alzheimer’s disease and may complement cerebrospinal fluid and positron emission tomography as a patient-screening tool in clinical trials.

Medical technology company LivaNova has announced the launch of SenTiva Duo, an implantable pulse generator that provides vagus nerve stimulation therapy for patients with drug-resistant epilepsy.

With a rising number of clinical studies demonstrating the potential benefits of psychedelic treatments for a wide range of behavioral health conditions, insurance plan provider Enthea aims to expand employer funding for these services.

Amylyx Pharmaceuticals Inc. announced completion of enrollment for a global, phase 3 clinical trial of AMX0035, an oral, fixed-dose medication for ALS.

A California-based biopharmaceutical company has announced the completion of its acquisition of Pherin Pharmaceuticals Inc., a drug development firm that specializes in neuropsychiatric and neuroendocrine issues.

Patients who survive a pregnancy-associated stroke are at lower risk for death and readmission compared with nonpregnant patients with stroke at 1 year; however, their risks were similar with longer follow-up, researchers reported.

What if Alzheimer’s disease, a neurological disorder that has confounded researchers since its identification in 1907, were not a brain disorder at all? What if it were instead an autoimmune disease that attacks the brain?

There has been a lot of attention about a proposed rule from the Federal Trade Commission that would prohibit many noncompetes. However, much of the discussion has been misleading, if not entirely wrong.

Women in China may be at greater risk for stroke events following menopause, according to a study published in Neurology.

Although well-tolerated with few adverse events, treatment with leriglitazone did not slow disease progression in men with adrenomyeloneuropathy compared with placebo, per a study published in Lancet Neurology.